Management

Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Background: Ardea Biosciences, Pfizer, Agouron Pharmaceuticals

Robert Rosen
President and Director
Background: Bayer HealthCare, Sanofi-Synthèlabo, Imclone

Stephen R. Davis
Executive VP, Chief Operating Officer and Director
Background: Ardea Biosciences and Neurogen

Brian Drazba
VP, Finance and Chief Financial Officer
Background: ISTA Pharmaceuticals, Insight Health Corp., Arthur Andersen & Co.

Mark S. Gelder, M.D.
Senior VP, Chief Medical Officer
Background: GE Healthcare Medical Diagnostics, Bayer Healthcare Pharmaceuticals, Wyeth

Michael Adam, Ph.D.
Senior VP, Regulatory Affairs and Quality
Background: Spectrum Pharmaceuticals, Pfizer/Agouron, Bristol-Myers Squibb

Paul Marshall
Senior VP, Technical Operations
Background: Amylin Pharmaceuticals, Amgen, Baxter International

Jesse Hollingsworth
VP, Sales
Background: Dendreon, ION Solutions, Amgen

Daniel Martin
VP, Marketing
Background: Dendreon, Amgen, Deloitte Consulting

Thomas Ottoboni, Ph.D.
VP, Pharmaceutical Development
Background: Talima Therapeutics, Point Biomedical, InSite Vision

Thomas Pitler, Ph.D.
VP, Business Development
Background: Chimerix, Neurogen

Joel Schaedler
VP, Market Access
Background: P4 Healthcare, Cardinal Health, Bionicare Medical Technologies


Barry D. Quart, Pharm.D.
Chief Executive Officer and Director

Barry D. Quart, Pharm.D. joined Heron Therapeutics in May 2013 as Chief Executive Officer and has served as a member of our board of directors since June 2012. Dr. Quart was most recently President and Chief Executive Officer of Ardea Biosciences, Inc., a biopharmaceutical company, since its founding in December 2006. Ardea was acquired by AstraZeneca PLC for $1.26 billion in June 2012. Previously, he was with Pfizer as Senior Vice President, Pfizer Global Research and Development and the director of Pfizer’s La Jolla Laboratories, where he was responsible for approximately 1,000 employees and an annual budget of almost $300 million. Prior to Pfizer’s acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. Agouron was acquired by Warner-Lambert for $2.1 billion in 1999. Dr. Quart joined Agouron in 1993 and was instrumental in the development and registration of Viracept, which went from the lab bench to new drug application approval in 38 months. Dr. Quart received his Pharm.D. degree from University of California, San Francisco.

Back to top

Robert Rosen
President and Director

Robert Rosen joined Heron Therapeutics as Senior Vice President and Chief Commercial Officer in October 2012 and was appointed to President in May 2013. Mr. Rosen has also served as a member of our board of directors since July 2012. Prior to joining Heron Therapeutics, he served as global head of oncology at Bayer HealthCare, where he was responsible for the development of the global oncology business unit for regions that included the Americas, Europe, Japan, and Asia Pacific from 2005 to 2011. During his tenure at Bayer Healthcare, he led the launch of Nexavar for the treatment of renal cell carcinoma and hepatocellular carcinoma. Nexavar’s worldwide sales in 2011 were $1.0 billion. He also led premarket activities for Stivarga for gastrointestinal stromal tumors and colon cancer and alpharadin for prostate cancer. From 2002 to 2005, Mr. Rosen was vice president of the oncology business unit at Sanofi-Synthèlabo, where he was responsible for the development of Sanofi’s U.S. oncology business and the launch of Eloxatin for colon cancer. Eloxatin U.S. sales in 2005, its third full year on the market, were $1.1 billion, ranking it among the industry’s most successful oncology drug launches. Mr. Rosen received a Bachelor of Science degree in Pharmacy from Northeastern University.

Back to top

Stephen R. Davis
Executive VP, Chief Operating Officer and Director

Stephen R. Davis joined Heron Therapeutics as Executive Vice President and Chief Operating Officer in May 2013 and has served as a member of our board of directors since June 2012. Mr. Davis was most recently Executive Vice President and Chief Operating Officer at Ardea Biosciences, Inc. He has completed numerous strategic transactions between biotechnology and pharmaceutical companies, including the recent $1.26 billion acquisition of Ardea by AstraZeneca PLC. Prior to Ardea, Mr. Davis served as President and Chief Executive Officer of Neurogen Corporation, a biopharmaceutical company acquired by Ligand Pharmaceuticals. Before becoming Neurogen’s Chief Executive Officer, Mr. Davis served in numerous executive roles at Neurogen completing multiple collaboration and asset acquisition and sale transactions with global pharmaceutical companies. Previously, Mr. Davis practiced as a corporate and securities attorney with a Wall Street law firm and as a Certified Public Accountant with a major accounting firm. Mr. Davis received his Bachelor of Science degree in Accounting from Southern Nazarene University and a J.D. from Vanderbilt University.

Back to top

Brian Drazba
VP, Finance and Chief Financial Officer

Brian Drazba joined Heron Therapeutics as Vice President of Finance and Chief Financial Officer in November 2013. Mr. Drazba brings nearly 30 years of financial management experience to Heron Therapeutics. Most recently, he was vice president of finance and chief accounting officer for ISTA Pharmaceuticals Inc. where he led the financial reporting, analysis, and tax functions. From 1992 to 2006, Mr. Drazba held positions of increasing responsibility within Insight Health Corp. (American Health Services Corp.), including senior vice president and chief accounting officer. Prior to his tenure at Insight Health, Mr. Drazba was employed by Arthur Andersen & Co. He is a licensed Certified Public Accountant in California and holds a Bachelor of Arts from University of San Diego.

Back to top

Mark S. Gelder, M.D.
Senior VP, Chief Medical Officer

Mark S. Gelder, M.D. joined Heron Therapeutics as Senior Vice President and Chief Medical Officer in December 2012. Dr. Gelder, most recently, was the vice president and global head of medical affairs and pharmacovigilance at GE Healthcare Medical Diagnostics. During his tenure, he led the global medical affairs strategy, including preparation and execution of medical launch plans. He was also responsible for global Phase IV and other post-approval commitment studies. Prior to GE Healthcare, Dr. Gelder was the vice president, global medical affairs oncology for Bayer Healthcare Pharmaceuticals, and was responsible for the global medical strategy supporting the launch of Nexavar®, Stivarga®, and Alpharadin® global launch programs. Dr. Gelder was also the global therapeutic area director of oncology at Wyeth, with a focus on the commercial launch of Torisel®. Earlier in his career, Dr. Gelder held roles of increasing responsibility at Pfizer, working on Sutent®, and was also a practicing gynecologic oncologist in both the academic and private sectors. Dr. Gelder received a bachelor’s of science degree from Colgate University, and his doctor of medicine from the University of Virginia’s School of Medicine.

Back to top

Michael Adam, Ph.D.
Senior VP, Regulatory Affairs and Quality

Michael Adam, Ph.D. joined A.P. Pharma as Senior Vice President of Regulatory Affairs and Quality in May 2011. Dr. Adam has been working with the Company as a consultant since July 2010 and brings over 25 years of drug development and pharmaceutical operations experience to the organization. He was most recently Senior Vice President of pharmaceutical operations at Spectrum Pharmaceuticals, Inc., where he oversaw CMC development, quality assurance and manufacturing. Prior to Spectrum, Dr. Adam served as Vice President, drug development operations at Anadys Pharmaceuticals, Inc., where he was responsible for regulatory affairs, quality assurance, pharmaceutical development, manufacturing and project management. He also has held senior positions with Pfizer, Inc., Agouron Pharmaceuticals, Inc. and Bristol-Myers Squibb Company. Dr. Adam earned his Ph.D. in Organic Chemistry at the Massachusetts Institute of Technology.

Back to top

Paul Marshall
Senior VP, Technical Operations

Paul Marshall joined Heron Therapeutics as Senior Vice President of Technical Operations in November 2013. Mr. Marshall has 27 years of experience in the development and commercialization of pharmaceutical products, including manufacturing and supply chain responsibility for 14 approved drugs and biologics, 3 of which achieved blockbuster (sales >$1B) status. Since 2006, Mr. Marshall has held ascending executive positions within Amylin Pharmaceuticals, Inc., including Senior Vice President, Operations. Prior to his work at Amylin, Mr. Marshall held executive manufacturing positions at Amgen, Inc. and Baxter International. He has held management positions at Creative BioMolecules, Welgen Manufacturing Partnership (now Amgen, Rhode Island), Repligen Corporation and Damon Biotech. Mr. Marshall received a Bachelor of Science and a Master of Science in Biology from the University of Massachusetts at Dartmouth and completed three years of post-graduate work concentrating in hematology and coagulation research at Brown University.

Back to top

Jesse Hollingsworth
VP, Sales

Jesse Hollingsworth joined Heron Therapeutics as Vice President of Sales in February 2013. Most recently, Mr. Hollingsworth served as the Senior Director of Group Purchasing Organizations (GPO) and Trade Strategy at Dendreon where he developed and implemented the company’s national GPO strategy. During this time, he was also responsible for building and managing relationships with top community oncologists for the company. Prior to his work at Dendreon, Mr. Hollingsworth was the Senior Director of Strategic Business Development and Marketing at ION Solutions, an Amerisource Bergen Specialty Group where he focused on GPO, payer and practice solutions. Earlier, he worked at Amgen, Inc., where, as the Marketing Director for the oncology business unit, Mr. Hollingsworth was responsible for US reimbursement and access programs for the Neulasta®, Neupogen® and Vectibix® franchises. Mr. Hollingsworth received a Bachelor of Science degree in Journalism and Communications from the University of Florida and a Master of Health Administration from the University of South Florida.

Back to top

Daniel Martin
VP, Marketing

Daniel Martin joined Heron Therapeutics as Vice President of Marketing in December 2012. Mr. Martin brings 14 years of diverse health care industry experience and nearly nine years of oncology marketing experience to Heron Therapeutics. Most recently he was the head of US marketing at Dendreon, reporting to the executive vice president and chief commercial officer. Prior to joining Dendreon, Mr. Martin spent 7 years in positions of increasing responsibility within Amgen's Oncology Business Unit. Mr. Martin worked on Amgen’s Aranesp® and Neulasta® franchises and then led the launch of XGEVA® into both oncology and urology. Prior to these roles, Mr. Martin led strategic planning and operations for Amgen’s oncology GPO team. Prior to Amgen, Mr. Martin worked as a management consultant with Deloitte Consulting where he specialized in pharmaceutical marketing and commercial operations. Mr. Martin holds a bachelor's of arts in economics and biology from the University of Virginia and received his master’s in business administration from the University of Pennsylvania’s Wharton School of Business.

Back to top

Thomas Ottoboni, Ph.D.
VP, Pharmaceutical Development

Thomas Ottoboni, Ph.D. joined Heron Therapeutics as Vice President of Pharmaceutical Development in March 2012. Prior to joining us, Dr. Ottoboni was Vice President of Research and Development at Talima Therapeutics, where he worked on the development of a drug delivery implant to treat onychomycosis. Dr. Ottoboni has also served as Executive Vice President of Strategy and Operations at Point Biomedical, where he developed several imaging and drug delivery systems. Previously, Dr. Ottoboni served as Manager of Systems Development and Drug Delivery Research for InSite Vision, where he developed ophthalmic pharmaceutical delivery systems and also served as Director of Drug Delivery at Vitaphore. Dr. Ottoboni is an inventor on more than 19 US patents in organic and macromolecular chemistry and received a B.S. degree in Chemistry as well as a Ph.D. in Organic Chemistry from the University of California, Berkeley.

Back to top

Thomas Pitler, Ph.D.
VP, Business Development

Thomas Pitler, Ph.D. joined Heron Therapeutics as Vice President of Business Development in September 2012. Most recently, Dr. Pitler was vice president of business development at Chimerix, where he was responsible for the company’s interactions with potential partners, leading the due diligence and negotiations process around the licensing of clinical stage programs, preclinical assets and underlying technology. Earlier, Dr. Pitler held the position of senior vice president, chief business and financial officer at Neurogen, Inc. (acquired by Ligand Pharmaceuticals). At Neurogen, Dr. Pitler established research and development collaborations with pharmaceuticals companies, including Merck and Aventis. Dr. Pitler was also a Research Assistant Professor at the University of Maryland School of Medicine and has held other academic positions. He received a B.A. in Biology and a Ph.D. in Physiology from Wake Forest University.

Back to top

Joel Schaedler
VP, Market Access

Joel Schaedler joined Heron Therapeutics as Vice President of Market Access in December 2012. Mr. Schaedler brings over 17 years of specialty pharmaceutical and healthcare distributor experience to Heron Therapeutics. Most recently, he was the senior vice president of business development at P4 Healthcare, which was acquired by Cardinal Health in 2010. Prior to his tenure at Cardinal Health, Mr. Schaedler was the regional vice president of sales for Bionicare Medical Technologies where he focused on the development of marketing strategies, physician targeting and creation of operational efficiencies. He has also held positions of increasing responsibilities with Amerisource Bergen Specialty, Centocor (acquired by Johnson & Johnson) and Sanofi-Aventis. Mr. Schaedler has a bachelor's of arts degree in business administration from Kent State University in Kent, Ohio.

Back to top